Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

This article has been updated

Abstract

The potent novel poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025, enhances the cytotoxicity of DNA-methylating agents and ionizing radiation by inhibiting DNA repair. We report here an investigation of the role of PARP in the cellular responses to inhibitors of topoisomerase I and II using NU1025. The cytotoxicity of the topoisomerase I inhibitor, camptothecin, was increased 2.6-fold in L1210 cells by co-incubation with NU1025. Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP. In contrast, NU1025 did not increase the DNA strand breakage or cytotoxicity caused by the topoisomerase II inhibitor etoposide. Exposure to etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival. However, in L1210 cells at least, it would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage. On the basis of these data, PARP inhibitors may be potentially useful in combination with topoisomerase I inhibitor anticancer chemotherapy. © 2001 Cancer Research Campaign

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. Banasik M, Komura H, Shimoyama M and Ueda K (1992) Specific inhibitors of poly(ADP-ribose)synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267: 1569–1575

    CAS  PubMed  Google Scholar 

  2. Barrows LR, Holden JA, Anderson M and D'Arpa P (1998) The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin-independent of DNA replication. Mutat Res 408: 103–110

    CAS  Article  PubMed  Google Scholar 

  3. Benjamin RC and Gill DM (1980) Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA: comparison of DNA molecules containing different types of strand breaks. J Biol Chem 255: 10502–10508

    CAS  PubMed  Google Scholar 

  4. Bernardi R, Negri C, Donzelli M, Torti M, Prosperi E and Scovassi AI (1995) Activation of poly(ADP-ribose) polymerase in apoptotic human cells. Biochimie 77: 378–384

    CAS  Article  PubMed  Google Scholar 

  5. Bernges F and Zeller WJ (1996) Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumour cell lines – with special reference to cisplatin. J Cancer Res Clin Oncol 122: 665–670

    CAS  Article  PubMed  Google Scholar 

  6. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT and Durkacz BW (1995) Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of pol(ADP-ribose)polymerase inhibitors. Br J Cancer 72: 849–856

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Bowman KJ, Curtin NJ, Golding BT, Griffin RJ and White A (1998) Potentiation of anticancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors, NU1025 and NU1064. Br J Cancer 78: 1269–1277

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Caldecott K and Jeggo P (1991) Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents. Mutat Res DNA Repair 255: 111–121

    CAS  Article  PubMed  Google Scholar 

  9. Caldecott KW, Aofouchi S, Johnson P and Shall S (1996) XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly(ADP-ribose) polymerase, and DNA ligaseIII is a novel molecular nick-sensor in vitro. Nucleic Acids Res 24: 4387–4394

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Chatterjee S, Cheng M-F, Trivedi D, Petzold SJ and Berger NA (1990) Camptothecin hypersensitivity in poly(adenine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun 1: 401–407

    Article  Google Scholar 

  11. Chatterjee S, Cheng M-F, Berger SJ and Berger NA (1994) Induction of M r 78,00 glucose-related stress protein in poly(adenosine diphosphate-ribose) polymerase-and nicotinamide adenine dinucleotide-deficient V70 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide. Cancer Res 54: 4405–4411

    CAS  PubMed  Google Scholar 

  12. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, de la Rubia G, Oliver J, Rolli V, Menissier-de Murcia J and de Murcia G (1999) Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81: 69–75

    CAS  Article  PubMed  Google Scholar 

  13. Darby MK, Schmitt B, Jongstra-Bilen J and Vosberg HP (1985) Inhibition of calf thymus type II topoisomerase by poly (ADP-ribosylation). EMBO J 4: 2129–2134

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Daugherty JP, Simpson TA, Jr. and Mullins DW, Jr. (1988) Effect of hyperthermia and doxorubicin on nucleoid sedimentation and poly(ADP-ribose)polymerase activity in L1210 cells. Cancer Chemother Pharmacol 21: 229–232

    CAS  Article  PubMed  Google Scholar 

  15. Delaney CA, Wang L-Z, Kyle S, Srinivasan S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Maegley K, Golding BT, Griffin RG and Newell DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(ADP-ribose) polymerase inhibitors in a panel of human tumour cell lines. Clin Cancer Res 6: 2860–2867

    CAS  PubMed  Google Scholar 

  16. de Murcia G and Menissier-de Murcia J (1994) Poly(ADP-ribose)polymerase: a molecular nick-sensor. TIBS 19: 172–176

    CAS  PubMed  Google Scholar 

  17. Eriksson C, Busk L and Brittebo EB (1996) 3-Aminobenzamide: effects on cytochrome P450-dependent metabolism of chemicals and on the toxicity of dichlobenil in the olfactory mucosa. Toxicol Appl Pharmacol 136: 324

    CAS  Article  PubMed  Google Scholar 

  18. Ferro AM and Olivera BM (1984) Poly (ADP-ribosylation) of DNA topoisomerase I from calf thymus, J Biol Chem 259: 547–554

    CAS  PubMed  Google Scholar 

  19. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW and Calvert AH (1995 a) The role of inhibitors of poly(ADP-ribose)polymerase as resistance modifying agents in cancer therapy. Biochimie 77: 364–367

    Article  Google Scholar 

  20. Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, Curtin NJ, Durkacz BW, Newell DR, Porteous JK and Golding BT (1995 b) Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anti-Cancer Drug Design 10: 507–514

    CAS  PubMed  Google Scholar 

  21. Griffin RJ, Srinivasan S, White AW, Bowman K, Calvert AH, Curtin NJ, Newell DR and Golding BT (1996) Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme, poly (ADP-ribose)polymerase. Pharmaceut Sci 2: 43–47

    CAS  Google Scholar 

  22. Halldorsson H, Gray DA and Shall S (1978) Poly(ADP-ribose)polymerase activity in nucleotide permeable cells. FEBS Lett 85: 349–352

    CAS  Article  PubMed  Google Scholar 

  23. Jeggo PA, Caldecott K, Pidsley S and Banks GR (1989) Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res 49: 7057–7063

    CAS  PubMed  Google Scholar 

  24. Kaufmann SH (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400: 185–211

    Article  Google Scholar 

  25. Kaufmann SH, Charron M, Burke PJ and Karp JE (1995) Changes in topoisomerase I levels and localisation during myeloid maturation in vitro and in vivo. Cancer Res 55: 1255–1260

    CAS  PubMed  Google Scholar 

  26. Kohn KW, Ewig RA, Erickson LC and Zwelling LA (1981) Measurement of strand breaks and cross-links by alkaline elution. DNA repair: a laboratory manual of research procedures, Friberg EC, Hanawalt PC (eds) pp. 379–401, Marcel Dekker Inc.: New York

    Google Scholar 

  27. Kubota M, Tanizawa A, Hashimoto H, Shimizu T, Takimoto T, Kitoh T, Akiyama Y and Mikawa H (1990) Cell type dependent activation of poly(ADP-ribose) synthesis following treatment with etoposide. Leukaemia Res 14: 371–375

    CAS  Article  Google Scholar 

  28. Marks DI and Fox RM (1991) DNA damage, poly(ADP-ribosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 42: 1859–1867

    CAS  Article  PubMed  Google Scholar 

  29. Mason M, Niedergang C, Schreiber V, Muller S, Menissier deMurcia J and deMurcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18: 3563

    Article  Google Scholar 

  30. Mattern MR, Mong S-M, Bartus HF, Mirabelli CK, Crooke ST and Johnson RK (1987) Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 47: 1793–1798

    CAS  PubMed  Google Scholar 

  31. Milam KM, Thomas GH and Cleaver JE (1986) Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase. Exp Cell Res 165: 260

    CAS  Article  PubMed  Google Scholar 

  32. Moses K, Harris AL and Durkacz BW (1988 a) Adenosine-diphosphoribosyl transferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochem Pharmacol 37: 2155

    CAS  Article  PubMed  Google Scholar 

  33. Moses K, Harris AL and Durkacz BW (1988 b) Synergistic enhancement of 6-thioguanine by ADP-ribosyltransferase inhibitors. Cancer Res 48: 5650

    CAS  PubMed  Google Scholar 

  34. Moses K, Willmore E, Harris AL and Durkacz BW (1990) Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide. Cancer Res 50: 1992

    CAS  PubMed  Google Scholar 

  35. Negri C, Bernardi R, Braghetti A, Astaldi Ricotti GCB and Scovassi IA (1993) The effect of the chemotherapeutic drug VP-16 on poly(ADP-ribosylation) in apoptotic HeLa cells. Carcinogenesis 14: 2559–2564

    CAS  Article  PubMed  Google Scholar 

  36. Pommier YM, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530–542

    CAS  Article  PubMed  Google Scholar 

  37. Strumberg D, Pilon AA, Smith M, Malkas LH and Pommier Y (1999) Selective inhibition of lagging strand DNA replication by camptothecin-induced topoisomerase I-poisoning. Proc Am Assoc Cancer Res 40: 208

    Google Scholar 

  38. Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM and Sebolt-Leopold JS (1991) Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase. Anti-Cancer Drug Design 7: 107–117

    Google Scholar 

  39. Tanizawa A, Kubota M, Hashimoto H, Shimizu T, Takimoto T, Kitoh T, Akiyama Y and Mikawa H (1989) VP-16-induced nucleotide pool changes and poly (ADP-ribose) synthesis: the role of VP-16 in interphase death. Exp Cell Res 185: 237–246

    CAS  Article  PubMed  Google Scholar 

  40. Yang S-W, Burgin AB, Huizenga BN, Robertson CA, Yao KC and Nash HA (1996) A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type 1 topoisomerases. Proc Natl Acad Sci USA 93: 11534–11539

    CAS  Article  PubMed  Google Scholar 

  41. Zwelling LA, Kerrigan D, Pommier Y, Michaels S, Steren A and Kohn KW (1982) Formation and resealing of intercalator-induced DNA strand breaks in permeabilised L1210 cells without the stimulated synthesis of poly (ADP-ribose). J Biol Chem 257: 8957–8963

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to N J Curtin.

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Bowman, K., Newell, D., Calvert, A. et al. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84, 106–112 (2001). https://doi.org/10.1054/bjoc.2000.1555

Download citation

Keywords

  • poly(ADP-ribose) polymerase
  • topoisomerase I
  • topoisomerase II
  • cytotoxicity
  • DNA damage

Further reading

Search

Quick links